Literature DB >> 24369413

Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study.

Timucin Kasifoglu1, Sule Yasar Bilge, Ismail Sari, Dilek Solmaz, Soner Senel, Hakan Emmungil, Levent Kilic, Sibel Yilmaz Oner, Fatih Yildiz, Sedat Yilmaz, Duygu Ersozlu Bakirli, Muge Aydin Tufan, Sema Yilmaz, Veli Yazisiz, Yavuz Pehlivan, Cemal Bes, Gozde Yildirim Cetin, Sukran Erten, Emel Gonullu, Tuncer Temel, Fezan Sahin, Servet Akar, Kenan Aksu, Umut Kalyoncu, Haner Direskeneli, Eren Erken, Bunyamin Kisacik, Mehmet Sayarlioglu, Cengiz Korkmaz.   

Abstract

OBJECTIVE: The primary aim of this study was to investigate the prevalence of amyloidosis and its related factors in a large number of FMF patients.
METHODS: Fifteen centres from the different geographical regions of Turkey were included in the study. Detailed demographic and medical data based on a structured questionnaire and medical records were collected. The diagnosis of amyloidosis was based on histological proof of congophilic fibrillar deposits in tissue biopsy specimens.
RESULTS: There were 2246 FMF patients. The male/female ratio was 0.87 (1049/1197). The mean age of the patients was 34.5 years (S.D. 11.9). Peritonitis was the most frequent clinical finding and it was present in 94.6% of patients. Genetic testing was available in 1719 patients (76.5%). The most frequently observed genotype was homozygous M694V mutation, which was present in 413 (24%) patients. Amyloidosis was present in 193 patients (8.6%). Male sex, arthritis, delay in diagnosis, M694V genotype, patients with end-stage renal disease (ESRD) and family history of amyloidosis and ESRD were significantly more prevalent in patients with amyloidosis compared with the amyloidosis-negative subjects. Patients with homozygous M694V mutations had a 6-fold higher risk of amyloidosis compared with the other genotypes (95% CI 4.29, 8.7, P < 0.001).
CONCLUSION: In this nationwide study we found that 8.6% of our FMF patients had amyloidosis and homozygosity for M694V was the most common mutation in these patients. The latter finding confirms the association of homozygous M694V mutation with amyloidosis in Turkish FMF patients.

Entities:  

Keywords:  amyloidosis; familial Mediterranean fever; prevalence

Mesh:

Substances:

Year:  2013        PMID: 24369413     DOI: 10.1093/rheumatology/ket400

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  25 in total

1.  The importance of Mediterranean fever gene in familial Mediterranean fever.

Authors:  Demet Yalçın Kehribar; Metin Özgen
Journal:  Eur J Rheumatol       Date:  2020-07-21

2.  The role of MEFV mutations in the concurrent disorders observed in patients with familial Mediterranean fever.

Authors:  Sabri Güncan; N Şule Y Bilge; Döndü Üsküdar Cansu; Timuçin Kaşifoğlu; Cengiz Korkmaz
Journal:  Eur J Rheumatol       Date:  2016-09-01

3.  Predictors of AA amyloidosis in familial Mediterranean fever.

Authors:  Nikolay A Mukhin; Lidiya V Kozlovskaya; Marina V Bogdanova; Vilen V Rameev; Sergey V Moiseev; Armine Kh Simonyan
Journal:  Rheumatol Int       Date:  2015-01-14       Impact factor: 2.631

Review 4.  Familial Mediterranean fever, review of the literature.

Authors:  Mansour Alghamdi
Journal:  Clin Rheumatol       Date:  2017-06-18       Impact factor: 2.980

Review 5.  Familial Mediterranean fever: An updated review.

Authors:  İsmail Sarı; Merih Birlik; Timuçin Kasifoğlu
Journal:  Eur J Rheumatol       Date:  2014-03-01

Review 6.  What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review.

Authors:  Burak Erer; Erkan Demirkaya; Seza Ozen; Tilmann Kallinich
Journal:  Rheumatol Int       Date:  2015-12-28       Impact factor: 2.631

7.  Vitamin D status, serum lipid concentrations, and vitamin D receptor (VDR) gene polymorphisms in Familial Mediterranean fever.

Authors:  Turan Turhan; Halef Okan Doğan; Nihal Boğdaycioğlu; Nilnur Eyerci; Ahmet Omma; İsmail Sari; Ahmet Yeşilyurt; Yaşar Karaaslan
Journal:  Bosn J Basic Med Sci       Date:  2018-02-20       Impact factor: 3.363

8.  Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever.

Authors:  Pinar Cetin; Ismail Sari; Betul Sozeri; Ozlem Cam; Merih Birlik; Nurullah Akkoc; Fatos Onen; Servet Akar
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

9.  Disease Severity and Genotype Affect Physical Growth in Children With Familial Mediterranean Fever.

Authors:  Rabia Miray Kişla Ekinci; Sibel Balci; Eray Akay; Dilek Doğruel; Derya Ufuk Altintaş; Mustafa Yilmaz
Journal:  Arch Rheumatol       Date:  2019-01-28       Impact factor: 1.472

10.  The unsolved mystery of MEFV variants variable expressivity in Familial Mediterranean Fever.

Authors:  Alessandro Stella; Piero Portincasa
Journal:  Intern Emerg Med       Date:  2022-07-09       Impact factor: 5.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.